Antimicrobial Usage and Resistance in Makkah Region Hospitals: A Regional Point Prevalence Survey of Public Hospitals

Abdul Haseeb 1,* , Hani Saleh Faidah 2 , Manal Algethamy 3 , Saleh Alghamdi 4 , Ghaidaa Ali Alhazmi 5 , Afnan Owedah Alshomrani 6 , Bashair Rjyan Alqethami 7 , Hind Saeed Alotibi 8 , Maali Zayed Almutiri 9 , Khawlal Saad Almuqati 10 , Amjad Abdullah Albishi 11 , Mahmoud Essam Elrggal 1 , Ahmad Jamal Mahrous 15 , Asim Abdulaziz Khogeer 12,13 , Zikria Saleem 14 , Muhammad Shahid Iqbal 15 and Aziz Sheikh 16

(1) Background: Inappropriate use of antimicrobials and subsequently rise of antimicrobial resistance (AMR) remains a major public health priority. Over-prescribing of broad-spectrum antibiotics is one of the main contributing factors for the emergence of AMR. We sought to describe antimicrobial prescribing trends among patients in public hospitals in Makkah hospitals. (2) Method: We undertook a point prevalence survey (PPS) in six hospitals in Makkah, Saudi Arabia, from January 2019 to July 2019. The survey included all the inpatients receiving antimicrobials on the day of PPS. Data was collected using the Global point prevalence survey (PPS) tool developed by the University of Antwerp, Belgium. (3) Results: Of 710 hospitalized patients, 447 patients (61.9%) were treated with one or more antimicrobials during the study period. The average bed occupancy among six hospitals was 74.4%. The majority of patients received antimicrobials parenterally (90.3%). Of the total prescribed antimicrobials, 415 (53.7%) antimicrobials were used in medical departments, 183 (23.7%) in surgical departments, and 175 (22.6%) in ICUs.

Abstract: (1) Background: Inappropriate use of antimicrobials and subsequently rise of antimicrobial resistance (AMR) remains a major public health priority. Over-prescribing of broad-spectrum antibiotics is one of the main contributing factors for the emergence of AMR. We sought to describe antimicrobial prescribing trends among patients in public hospitals in Makkah hospitals. (2) Method: We undertook a point prevalence survey (PPS) in six hospitals in Makkah, Saudi Arabia, from January 2019 to July 2019. The survey included all the inpatients receiving antimicrobials on the day of PPS. Data was collected using the Global point prevalence survey (PPS) tool developed by the University of Antwerp, Belgium. (3) Results: Of 710 hospitalized patients, 447 patients (61.9%) were treated with one or more antimicrobials during the study period. The average bed occupancy among six hospitals was 74.4%. The majority of patients received antimicrobials parenterally (90.3%). Of the total prescribed antimicrobials, 415 (53.7%) antimicrobials were used in medical departments, 183 (23.7%) in surgical departments, and 175 (22.6%) in ICUs. Pneumonia (17.3%), skin and soft tissue infections (10.9%), and sepsis (6.6%) were three common clinical indications.
Antimicrobials are commonly used to treat or prevent bacterial infections. Some antimicrobials may be used inappropriately—for example, if not indicated or suboptimal selection, dose, route of administration, or duration [1,2]. Antimicrobial selection pressure contributes to the emergence and spread of antimicrobial resistance (AMR) [3,4]. In the last few decades, the inappropriate use of antimicrobials and the rise of AMR has emerged as major global public health concern [5]. In an attempt to address the risks posed by AMR, the World Health Organization (WHO) recommends the initiation of antimicrobial stewardship programs (ASPs) to identify and monitor antimicrobial use and reduce the burden of AMR [6,7]. Economically developed countries have started implementing ASP to resolve this issue; however, in economically developing countries, the scenario is quite different. In the Gulf region, there is still a lack of knowledge and worrying attitudes and belief concerning antimicrobial use [8].

Saudi Arabia is the cornerstone of pilgrimage for Muslims from all over the world for Hajj/Umrah, with these religious rites centered on the holy city of Makkah. The extreme congestion of Saudi and non-Saudi populations results in the occurrence and spread of various infectious diseases, specifically when the healthcare system is not well-established [9,10]. A national point prevalence survey (PPS) carried out in 26 hospitals in Saudi Arabia reported that 45.7% of antimicrobials are used in surgical departments, and 59.6% of patients received at least one antimicrobial in Makkah hospital, representing the fourth highest antimicrobial usage nationally [11]. Another PPS was carried out in one hospital in Jeddah, Saudi Arabia reporting high antimicrobial usage in this region [12,13]. The uncontrolled usage of antimicrobials has the potential to contribute to the spread of antimicrobial-resistant agents nationally, as well as globally [14]. Information on antimicrobial use and AMR from PPSs could be used to design, implement and assess the effects of antimicrobial policies [15]. Limited data regarding antimicrobial use by using PPS tool is available in hospitals of the Makkah region dealing with pilgrims specifically. Moreover, data highlighting antimicrobial use and AMR among Makkah residents are not available. Therefore, this study was carried out to identify antimicrobial prescribing practices among patients in public and private hospitals in Makkah hospitals.

2. Materials and Methods

2.1. Study Design and Settings

A multicenter PPS of antimicrobial use was carried out among inpatients at six hospitals of Makkah, Saudi Arabia. The global point prevalence survey method was adopted, which aims to provide a standardized method for surveillance of antimicrobial use and to assess the quality of antimicrobial prescribing [12,13,16,17]. This survey was undertaken in six hospitals in the Makkah region.

2.2. Sampling and Recruitment of Hospitals

Participation of hospitals was voluntary. Different public sector hospitals were invited to participate in this survey. In case of refusal of the first hospital, the next health care setting was selected. The health care facilities providing acute care facilities were included.
Whereas the health care facilities providing only nursing care, rehabilitation centers, or psychiatric centers were not included.

2.3. Inclusion and Exclusion Criteria

All the inpatients present in the wards before 8:00 am and not discharged on the day of the survey were included in this study. Data was collected from those who received at least one antimicrobial for at least one clinical condition or prophylaxis at the time of the survey. Outpatients and patients undergoing any surgery at the time of the survey were excluded. Patients who did not receive antimicrobials or were admitted to long-term care wards, emergency departments, and day-care wards (e.g., renal dialysis ward) were also excluded from this survey.

2.4. Case Definition and Data Collection

Antibiotics were classified according to the anatomical therapeutic chemical (ATC) classification system developed by the WHO Collaborating Centre for Drug Statistics Methodology in Oslo, Norway. Only antimicrobials for systemic use (ATC J01) were included in the survey. Two forms were used to collect data: one to collect about the relevant ward/department and the second to gather information related to patients who were on systematic antimicrobial agents during PPS. The data collected from ward/department included: the type of ward/department (medical, surgical, or intensive care unit), the total number of beds, all admitted patients, and the number of patients on antimicrobials. The patient form was designed to obtain information about patients and the antibiotics they were taking. The data obtained included: the patient’s characteristics; details of their prescribed antimicrobials, such as drug name, unit dose, frequency, and reasons for prescribing. Compliance with clinical guidelines was also assessed. Compliance was measured by assessing prescribing patterns against institutional antimicrobial prescribing guidelines. All data collectors had a training session about key objectives and data collection approach for this survey. A pilot survey was carried out by collecting data from 5 patients to review the quality of protocol. Data were collected from January 2019 to July 2019.

2.5. Timeline

Included hospitals had to be completed PPS within two to three weeks from the first day of data collection. To minimize the effect of movement of patients between wards and within hospitals, each ward was completely surveyed within one day. Due to limited staff availability, no survey was carried out during weekends or bank holidays.

3. Results

A total of six hospitals with 950 beds were surveyed. Of 710 hospitalized patients, 447 patients (61.9%) were treated with one or more antimicrobials during the study period. The demographics and clinical characteristics of inpatients are described in Table 1. The average bed occupancy among six hospitals was 74.4%. The total number of prescribed antimicrobials was 774, and of these, 90.3% of antimicrobials were administered parenterally, and 9.7% of antimicrobials were given orally. The majority of patients (52.0%) received antimicrobials for community-acquired infections. Most of the surveyed patients were admitted to medical departments (53.7%), followed by surgical wards (23.7%) and intensive care units (ICUs) (22.6%). Additionally, empirical treatment (85.4%) was more common.

Compliance with clinical guidelines was also evaluated; most of the hospitals were compliant to guidelines, while the highest compliance rate was in H6 hospitals, with a 78.9% compliance rate, while the least compliance rate was shown in H2 hospitals. The use of the main antimicrobial classes was also evaluated and described in Table 2. The total number of antibacterial agents prescribed for systemic use (J01) was 744, which represents 96.2% of the total antimicrobial agents used. The antimicrobials included J01A;1.8%, J01B;0.1%, J01C;19.5%, J01D; 36.9%, J01E; 0.4%, J01F;10%, J01G; 3%, J01M;9.6%, J01X;15%. 
Table 1. Overall antibiotic use prevalence.

| Characteristics               | H1       | H2       | H3       | H4       | H5       | H6       | Total   | Range |
|-------------------------------|----------|----------|----------|----------|----------|----------|---------|-------|
| **Hospital Type**             |          |          |          |          |          |          |         |       |
| Total beds                    | 175      | 180      | 118      | 174      | 283      | 20       | 950     | 20–283|
| Hospitalized patients         | 122 (69.7) | 152 (84.4) | 96 (81.3) | 121 (69.5) | 202 (71.3) | 15 (75.0) | 710 (74.7) | 69.5–84.4 |
| Prescribed antibiotics (per patient) | 140 (1.7) | 150 (1.8) | 129 (1.9) | 106 (1.8) | 229 (1.6) | 19 (1.3) | 773 (1.7) | 1.3–1.9 |
| **Departments**               |          |          |          |          |          |          |         |       |
| Surgical Department           | 32 (22.9) | 25 (16.7) | 33 (25.6) | 12 (11.3) | 81 (35.4) | -        | 183 (23.7) | 11.3–35.4 |
| Medical Department            | 74 (52.9) | 125 (83.3) | 39 (30.2) | 71 (67.0) | 106 (46.3) | -        | 415 (33.7) | 30.2–83.3 |
| Intensive Care Unit           | 34 (24.3) | -        | 57 (44.2) | 23 (21.7) | 42 (18.3) | -        | 175 (22.6) | 0–100 |
| **Gender**                    |          |          |          |          |          |          |         |       |
| Male                          | 74 (52.9) | 42 (28.0) | 70 (54.3) | 70 (66.0) | 143 (62.4) | 10 (52.6) | 409 (52.9) | 28.0–66.0 |
| Female                        | 66 (47.1) | 105 (70.0) | 54 (41.9) | 36 (34.0) | 86 (37.6) | 9 (47.4) | 356 (46.1) | 34.0–70.0 |
| **Route of administration**   |          |          |          |          |          |          |         |       |
| Oral                          | 13 (9.3) | 15 (10.0) | 5 (3.9)   | 12 (11.3) | 25 (10.9) | 5 (26.3) | 75 (9.7) | 3.9–26.3 |
| Parenteral                    | 127 (90.7) | 135 (90.0) | 124 (96.1) | 94 (88.7) | 204 (89.1) | 14 (73.7) | 698 (90.3) | 73.7–96.1 |
| Indication                    |          |          |          |          |          |          |         |       |
| Community-acquired infection  | 56 (40.0) | 132 (88.0) | 37 (28.7) | 44 (31.5) | 114 (49.8) | 19 (100.0) | 402 (52.8) | 40.0–100.0 |
| Hospital-acquired infection   | 73 (52.1) | 18 (12.0) | 27 (20.8) | 40 (37.6) | 60 (26.2) | -        | 218 (28.1) | 0.0–52.1 |
| Medical prophylaxis (single dose) | -        | -        | 2 (1.9)    | 5 (2.2)   | -        | -        | 7 (0.9) | 0.0–2.2 |
| Surgical prophylaxis (one day) | 4 (2.9) | -        | 13 (10.1) | 4 (3.8)   | 11 (4.8) | -        | 32 (4.1) | 0.0–10.1 |
| Surgical prophylaxis (>1 day) | 4 (2.9) | -        | 1 (0.8)    | 8 (8.5)   | 26 (11.4) | -        | 40 (5.2) | 0.0–11.4 |
| Others                        | -        | -        | 47 (36.5) | 2 (1.9)   | 6 (2.6)   | -        | 55 (7.1) | 0.0–36.5 |
| **Treatment**                 |          |          |          |          |          |          |         |       |
| Empirical therapy             | 108 (77.1) | 143 (95.3) | 107 (82.9) | 89 (84.0) | 194 (84.7) | 19 (100.0) | 660 (85.4) | 77.1–100.0 |
| Targeted therapy              | 32 (22.9) | 7 (4.7) | 22 (17.1) | 17 (16.0) | 35 (15.3) | -        | 113 (14.6) | 0.0–22.9 |
| Guideline’s compliance        |          |          |          |          |          |          |         |       |
| Yes                           | 70 (50.0) | 12 (8.0) | 54 (41.9) | 17 (16.0) | 57 (24.9) | 14 (78.9) | 225 (29.1) | 8.0–78.9 |
| No                            | 65 (46.4) | -        | 18 (9.4)  | 10 (9.4)  | 31 (13.5) | 4 (21.1) | 111 (14.4) | 0.0–46.4 |
| NA                            | 5 (3.6) | 138 (92.0) | 49 (38.0) | 75 (70.8) | 116 (50.7) | -        | 383 (49.5) | 0.0–90.2 |
| Stop date documented          | 35 (25.0) | 57 (38.0) | 29 (22.5) | 49 (46.2) | 74 (32.3) | 16 (84.2) | 260 (33.6) | 22.5–84.2 |
| Reason on notes               | 79 (56.4) | 54 (36.0) | 84 (65.1) | 56 (52.8) | 150 (65.5) | 16 (84.2) | 439 (56.8) | 36.0–84.2 |
| **Culture Reports**           | 32       | 7        | 22       | 34       | 37       | 0        | 132     | 0–37  |

Table 2. Use the prevalence of main antibiotics classes.

| Antibiotics                                    | n (%) |
|------------------------------------------------|-------|
| ANTIBACTERIALS FOR SYSTEMIC USE (J01)         | 744 (96.2) |
| Tetracyclines (J01A)                          | 14 (1.8) |
| Amphenicols (J01B)                            | 1 (0.1) |
| Penicillins (J01C)                            | 151 (19.5) |
| Cephalosporins and Penams (J01D)              | 285 (36.9) |
| Sulphonamides and trimethoprim (J01E)         | 3 (0.4) |
| Macrolides and lincosamides (J01F)            | 77 (10.0) |
| Aminoglycosides (J01G)                        | 23 (3.0) |
| Quinolones (J01M)                             | 74 (9.6) |
| Other antibacterials (J01X)                   | 116 (15.0) |
| Antimycotics for systemic use(J02)            | 8 (1.0) |
| Antimycobacterials FOR SYSTEMIC USE (J04)     | 11 (1.4) |
| Antivirals FOR SYSTEMIC USE (J05)             | 8 (1.0) |
| Antiprotozoals (P01)                          | 2 (0.3) |

The most common indications and used antimicrobials are reported in Table 3. The most common indication for antibiotics prescription was pneumonia, with 134 prescriptions (17.3%), while the least prevalent indication was both the cardiovascular system and prophylactic gastrointestinal tract infections, representing 25 prescriptions (3.2%). Ceftriaxone was the most commonly used antibiotic, which was prescribed in 116 (15%) of patients, followed by piperacillin, with an enzyme inhibitor in 84 (10.9%) of the prescriptions. At the same time, the least prescribed antibiotic was ciprofloxacin in 25 (3.2%) prescriptions. As for the type of bacteria isolated from cultures, Methicillin-resistant Staphylococcus aureus (MRSA) was the most frequently isolated bacterial strain in 35.0% of cultures, while carbapenem-producing gram-negative bacilli were the least common isolated bacterial strain, which was isolated in less than 5% of the cultures as shown in Figure 1.
Table 3. Top 10 indications and antibiotics.

| No. | Indications      | n (%)  | Antibiotics        | n (%)  |
|-----|------------------|--------|--------------------|--------|
| 1   | Pneumonia        | 134 (17.3) | Ceftriaxone      | 116 (15.0) |
| 2   | Others           | 111 (14.4) | Piperacillin, enzyme inhibitor | 84 (10.9) |
| 3   | SST              | 84 (10.9) | Metronidazole      | 55 (7.1) |
| 4   | Unknown          | 67 (8.7) | Cefuroxime         | 45 (5.8) |
| 5   | SEPSIS           | 51 (6.6) | Levofoxcin         | 45 (5.8) |
| 6   | OBGY             | 42 (5.4) | Meropenam          | 42 (5.4) |
| 7   | BJ               | 38 (4.9) | Clindamycin        | 41 (5.3) |
| 8   | CNS              | 28 (3.6) | Vancomycin         | 37 (4.8) |
| 9   | CVS              | 25 (3.2) | Cefazolin          | 35 (4.5) |
| 10  | P, GIT           | 25 (3.2) | Ciprofloxacin      | 25 (3.2) |

BJ: Bone and Joint, CNS: Central Nervous System, GIT: Gastro-Intestinal Tract, OBGY: Obstetric or Gynaecological, P: Prophylaxis, SST: Skin and Soft Tissues.

Figure 1. Common pathogens reported in hospitals.

4. Discussion

Antimicrobial resistance has been a global hazard over the past two decades. It has been attributed to the abuse of antibiotics in both in-hospital and outpatients’ settings, particularly broad-spectrum antibiotics. It has been revealed that almost up to 40% of hospitalized patients received antibiotics prescriptions, which are non-compliant with clinical guidelines [11]. Additionally, the excessive use of antibiotics for inappropriate indications or incomplete durations can also increase the burden of antimicrobial resistance. Hence, point prevalence studies can spot the light on areas of misuse and guide in developing national antibiotic use strategies [4].

The study demonstrated that up to 61.9% of patients were treated with at least one antimicrobial. This prevalence rate of antimicrobial use is higher than other PPS studies conducted in different regions of the world, including Germany (25.5%), Scotland (28.3%), Norway (16.6%), and Canada (17.3%) [18–21]. However, this is similar to some of the PPS surveys reported in LMICs, particularly the Asian countries, including Pakistan (77.6%), China (75.3%), and India (57.4%) [16,22,23]. Community-acquired infection was the main indication for antibiotics prescription, specifically pneumonia (17.3%); this is similar though to the study reported in Japan (20%) and Pakistan (34.2%), where most of the patients received antimicrobials for the treatment of community-acquired infections [16,24]. The majority of the patients received antimicrobials parenterally that were similar to previously reported studies [20].
A difference in prescribing patterns was observed among these hospitals. The number of antimicrobials per patient was 1.76, which is almost similar to the study conducted in Nigeria (1.77), Japan (1.66), and Pakistan (1.64) [23,25,26]. The predominantly prescribed antimicrobials were cephalosporins which is similar to other previous studies conducted in Eastern Asia, Southern Asia, Africa, and Northern Europe [16,20,22–25]. Another study conducted in Saudi Arabia also reported that cephalosporins were the most frequently prescribed antimicrobial class in 26 MOH hospitals [11]. The antimicrobial usage was higher in medical departments (53.7%). However, in Turkey, antimicrobial use was higher in surgical ICU wards (81%) [26]. In South Africa, 83% of the prescriptions were modified based on culture results, while in the present study, only 30% of culture reports were found from the six hospitals [27].

The most recent point prevalence survey was performed in Ghana to examine antibiotic use as part of an antibiotic stewardship program in two hospitals [28]. It showed compliance with guidelines between 50–67%, which was lower than that measured in the present study. However, similar to the present study, most of the prescribed antibiotics were used systemically and on an empirical basis. Improvements in prescribing practices are required by developing evidence-based guidelines, improving laboratories, and retaining prescribers on the importance of empiric or targeted therapy. The present study could be the basis for initiating and implementing the ASPs for different scales of the hospital. Nevertheless, the present study had some limitations. All the included hospitals were only in Makkah city, which makes extrapolating the findings to other cities in Saudi Arabia difficult. Secondly, data of some patients were incomplete to assess the diagnosis of infectious disease, which could affect the PPS results. This is considered the first study in Makkah city to evaluate antibiotic use through a point prevalence survey in multiple hospitals.

5. Conclusions

We found a very high prevalence of antibiotic use in Makkah hospitals. Public health decision-makers in Makkah city should take these findings into consideration to update national policies for antibiotic use in order to find ways of curbing the growth of AMR. These policies are particularly essential for community-acquired infections. Additionally, similar studies are required in other areas in Saudi Arabia to provide comparative national estimates for other parts of the Kingdom.

Author Contributions: Conceptualization, A.H., H.S.F., M.A., S.A. and A.S.; methodology, A.H., S.A., AJM, G.A.A., A.O.A., H.S.A., K.S.A., M.Z.A., A.A.A. and B.R.A.; Review, A.H., S.A. and Z.S.; analysis, A.H., S.A. and M.E.E.; resources, A.H., M.E.E. and B.R.A.; writing—original draft preparation, A.H., A.A.K., S.A., AJM, Z.S., G.A.A. and A.O.A.; writing—review and editing, A.S., Z.S., H.S.F., A.A.K., M.S.I. and A.S.; supervision, H.S.F., M.A., K.S.A. and A.S.; funding acquisition, A.H., M.E.E. and H.S.F. All authors have read and agreed to the published version of the manuscript.

Funding: The authors would like to thank the Deanship of Scientific Research at Umm Al-Qura University for the continuous support. This work was supported financially by the Deanship of Scientific Research at Umm Al-Qura University to Abdul Haseeb (Grant Code: 19-MED-1-01-0029).

Institutional Review Board Statement: Institutional review board approved this study from the general directorate of health, Makkah, Saudi Arabia, by approval number (H-02-K-076-0119-081) granted on 20/01/2019.

Informed Consent Statement: Patient consent was waived because it was a simple observational study.

Data Availability Statement: All statistical analysis was performed using IBM SPSS statistics software (IBM Corp., Armonk, NY, United States) for Windows, Version 22.0. Descriptive analyses were undertaken to calculate frequency, percentage, median, and mode. Continuous variables are expressed as the median and range.
Acknowledgments: We would like to thank all data collectors and the ministry of health hospitals’ research administrators for facilitating the data collection process in all hospitals. We would also like to thank Faadi Baksh, Jihad Nassir, Abdulhnan Almehmad, Abdulaziz Sayed, and Hassan Banasir for their efforts to supervise the data collection process with the research team. We also would like to acknowledge the assistance of Global Point Prevalence Survey, by University of Antwerp and sponsored by bioMérieux.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Plachouras, D.; Kärki, T.; Hansen, S.; Hopkins, S.; Lytyikäinen, O.; Moro, M.L.; Reilly, J.; Zarb, P.; Zingg, W.; Kinross, P.; et al. Antimicrobial use in European acute care hospitals: Results from the second point prevalence survey (PPS) of healthcare-associated infections and antimicrobial use, 2016 to 2017. *Eurosurveillance* 2018, 23, 1800393. [CrossRef] [PubMed]

2. Saleem, Z.; Saeed, H.; Hassali, M.A.; Godman, B.; Asif, U.; Yousaf, M.; Ahmed, Z.; Riaz, H.; Raza, S.A. Pattern of inappropriate antibiotic use among hospitalized patients in Pakistan: A longitudinal surveillance and implications. *Antimicrob. Resist. Infect. Control* 2019, 8, 188. [CrossRef] [PubMed]

3. Gandra, S.; Singh, S.K.; Jinka, D.R.; Kanithi, R.; Chikkappa, A.K.; Sharma, A.; Dharmapalan, D.; Vasudevan, A.K.; Tunga, O.; Akula, A.; et al. Point prevalence surveys of antimicrobial use among hospitalized children in six hospitals in India in 2016. *Antibiotics* 2017, 6, 19. [CrossRef] [PubMed]

4. Saleem, Z.; Hassali, M.A.; Godman, B.; Versporten, A.; Hashmi, F.K.; Saeed, H.; Saleem, F.; Salman, M.; Rehman, I.U.; Khan, T.M. Point prevalence surveys of antimicrobial use: A systematic review and the implications. *Expert Rev. Anti-Infect. Ther.* 2020, 18, 897–910. [CrossRef]

5. Tillotson, G.S.; Zinner, S.H. Burden of antimicrobial resistance in an era of decreasing susceptibility. *Expert Rev. Anti-Infect. Ther.* 2017, 15, 663–676. [CrossRef] [PubMed]

6. Hogan, K.-A.; Gazarin, M.; Lapenskie, J. Development and implementation of an antimicrobial stewardship program in a rural hospital. *Can. J. Hosp. Pharm.* 2016, 69, 403. [CrossRef]

7. File, T.M., Jr.; Srinivasan, A.; Bartlett, J.G. Antimicrobial stewardship: Importance for patient and public health. *Clin. Infect. Dis.* 2014, 59 (Suppl. 3), S93–S96. [CrossRef]

8. Emeka, P.M.; Al-Omar, M.; Khan, T.M. Public attitude and justification to purchase antibiotics in the Eastern region Al Ahsa of Saudi Arabia. *Saudi Pharm. J.* 2014, 22, 550–554. [CrossRef]

9. Memish, Z.A.; Venkatsh, S.; Ahmed, Q.A. Travel epidemiology: The Saudi perspective. *Int. J. Antimicrob. Agents* 2003, 21, 96–101. [CrossRef]

10. Ahmed, Q.A.; Arabi, Y.M.; Memish, Z.A. Health risks at the Hajj. *Lancet* 2006, 367, 1008–1015. [CrossRef]

11. Al Matar, M.; Enani, M.; Binsaleh, G.; Roushyd, H.; Alokaili, D.; Al Bannai, A.; Khidir, Y.; Al-Abdely, H. Point prevalence survey of antibiotic use in 26 Saud hospitals in 2016. *J. Infect. Public Health* 2019, 12, 77–82. [CrossRef]

12. Versporten, A.; Bielicki, J.; Draper, N.; Sharland, M.; Goossens, H.; Group, A.P.; Calle, G.M.; Garrahan, J.P.; Clark, J.; Cooper, C.; et al. The Worldwide Antibiotic Resistance and Prescribing in European Children (ARPEC) point prevalence survey: Developing hospital-quality indicators of antibiotic prescribing for children. *J. Antimicrob. Chemother.* 2016, 71, 1106–1117. [CrossRef] [PubMed]

13. Versporten, A.; Zarb, P.; Caniaux, I.; Gros, M.-F.; Draper, N.; Miller, M.; Jarlier, V.; Nathwani, D.; Goossens, H.; Koraqi, A.; et al. Antimicrobial consumption and resistance in adult hospital inpatients in 53 countries: Results of an internet-based global point prevalence survey. *Lancet Glob. Health* 2018, 6, e619–e629. [CrossRef]

14. El Zowalaty, M.; Belkina, T.; Bahashwan, S.A.; Tebbens, J.D.; Abdel-Salam, H.A.; Khalil, A.I.; Daghriry, S.I.; Gahtani, M.A.; Madkhaly, F.M.; Nohi, N.I.; et al. Knowledge, awareness, and attitudes toward antibiotic use and antimicrobial resistance among Saudi population. *Int. J. Clin. Pharm.* 2016, 38, 1261–1268. [CrossRef] [PubMed]

15. Skoog, G.; Struve, J.; Cars, O.; Hanberger, H.; Odenholt, I.; Prag, M.; Skärlund, K.; Ullerud, Y.; Erntell, M. Repeated nationwide point-prevalence surveys of antimicrobial use in Swedish hospitals: Data for actions 2003–2010. *Eurosurveillance* 2016, 21, 30264. [CrossRef]

16. Saleem, Z.; Hassali, M.A.; Versporten, A.; Godman, B.; Hashmi, F.K.; Goossens, H.; Saleem, F. A multicenter point prevalence survey of antibiotic use in Punjab, Pakistan: Findings and implications. *Expert Rev. Anti-Infect. Ther.* 2019, 17, 285–293. [CrossRef] [PubMed]

17. Chen, H.; Somani, J.; Wu, J.; Foo, G.; Chung, G. The Global Point Prevalence Survey of Antimicrobial Consumption and Resistance (GLOBAL-PPS): Comparison of results over the years2015–2019. *Int. J. Infect. Dis.* 2020, 101, 109. [CrossRef]

18. Hansen, S.; Sohr, D.; Piening, B.; Pena Diaz, L.; Gropmann, A.; Leistner, R.; Meyer, E.; Gastmeier, P.; Behnke, M. Antibiotic usage in German hospitals: Results of the second national prevalence study. *J. Antimicrob. Chemother.* 2013, 68, 2934–2939. [CrossRef] [PubMed]

19. Berild, D.; Ringertz, S.H.; Lelek, M. Appropriate antibiotic use according to diagnoses and bacteriological findings: Report of 12 point-prevalence studies on antibiotic use in a university hospital. *Scand. J. Infect. Dis.* 2002, 34, 56–60. [CrossRef]
20. Seaton, R.; Nathwani, D.; Burton, P.; McLaughlin, C.; MacKenzie, A.; Dundas, S.; Ziglam, H.; Gourlay, Y.; Beard, K.; Douglas, E. Point prevalence survey of antibiotic use in Scottish hospitals utilising the Glasgow Antimicrobial Audit Tool (GAAT). *Int. J. Antimicrob. Agents* 2007, 29, 693–699. [CrossRef] [PubMed]

21. Lee, C.; Walker, S.A.; Daneman, N.; Elligsen, M.; Palmay, L.; Coburn, B.; Simor, A. Point prevalence survey of antimicrobial utilization in a Canadian tertiary-care teaching hospital. *J. Epidemiol. Glob. Health* 2015, 5, 143–150. [CrossRef]

22. Ren, N.; Zhou, P.; Wen, X.; Li, C.; Huang, X.; Guo, Y.; Meng, L.; Gong, R.; Feng, L.; Fu, C.; et al. Point prevalence survey of antimicrobial use in Chinese hospitals in 2012. *Am. J. Infect. Control* 2016, 44, 332–339. [CrossRef] [PubMed]

23. Singh, S.; Sengupta, S.; Antony, R.; Bhattacharya, S.; Mukhopadhyay, C.; Ramasubramanian, V.; Sharma, A.; Sahu, S.; Nirkhiwale, S.; Gupta, S.; et al. Variations in antibiotic use across India: Multi-centre study through Global Point Prevalence survey. *J. Hosp. Infect.* 2019, 103, 280–283. [CrossRef] [PubMed]

24. Morioka, H.; Hirabayashi, A.; Iguchi, M.; Tomita, Y.; Kato, D.; Sato, N.; Hyodo, M.; Kawamura, N.; Sado, K.; Ichikawa, K.; et al. The first point prevalence survey of health care–associated infection and antimicrobial use in a Japanese university hospital: A pilot study. *Am. J. Infect. Control* 2016, 44, e119–e123. [CrossRef] [PubMed]

25. Oduyebo, O.; Olayinka, A.; Iregbu, K.; Versporten, A.; Goossens, H.; Nwajiobi-Princewill, P.; Jimoh, O.; Ige, T.; Aigbe, A.; Ola-Bello, O.; et al. A point prevalence survey of antimicrobial prescribing in four Nigerian tertiary hospitals. *Ann. Trop. Pathol.* 2017, 8, 42. [CrossRef]

26. Usluer, G.; Ozgunes, I.; Leblebicioglu, H.; The Turkish Antibiotic Utilization Study Group. A multicenter point-prevalence study: Antimicrobial prescription frequencies in hospitalized patients in Turkey. *Ann. Clin. Microbiol. Antimicrob.* 2005, 4, 16. [CrossRef] [PubMed]

27. Dlamini, N.N.; Meyer, J.C.; Kruger, D.; Kurdi, A.; Godman, B.; Schellack, N. Feasibility of using point prevalence surveys to assess antimicrobial utilisation in public hospitals in South Africa: A pilot study and implications. *Hosp. Pract.* 2019, 47, 88–95. [CrossRef]

28. Afriye, D.K.; Sefah, I.A.; Sneddon, J.; Malcolm, W.; McKinney, R.; Cooper, L.; Kurdi, A.; Godman, B.; Seaton, R.A. Antimicrobial point prevalence surveys in two Ghanaian hospitals: Opportunities for antimicrobial stewardship. *JAC-Antimicrob. Resist.* 2020, 2, dlaa001. [CrossRef]